Onivyde pegylated liposomal is a cancer medicine used in adults to treat a form of pancreatic cancer called metastatic adenocarcinoma of the pancreas. Metastatic means that the cancer has spread to other parts of the body. Onivyde pegylated liposomal is used together with other cancer medicines: - oxaliplatin, 5-fluorouracil and leucovorin, in patients whose cancer has never been treated, - 5-fluorouracil and leucovorin, in patients whose cancer has got worse despite treatment with the cancer medicine gemcitabine. Onivyde pegylated liposomal contains the active substance irinotecan. Pancreatic cancer is rare, and Onivyde pegylated liposomal was designated an ‘orphan medicine’ (a medicine used in rare diseases) on 9 December 2011. Further information on the orphan designation can be found here: [ema.europa.eu/medicines/human/orphan-designations/eu311933](https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-11-933).
Therapeutic Indication
### Therapeutic indication ONIVYDE pegylated liposomal is indicated: \- in combination with oxaliplatin, 5 fluorouracil (5 FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas, \- in combination with 5-FU and LV for the treatment of metastatic adenocarcinoma of the pancreas, in adult patients who have progressed following gemcitabine based therapy.
Therapeutic Area (MeSH)
N/AATC Code
L01CE02
ATC Item
irinotecan
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| irinotecan anhydrous free-base | N/A | irinotecan anhydrous free-base |
EMA Name
Onivyde pegylated liposomal (previously known as Onivyde)
Medicine Name
Onivyde pegylated liposomal (previously Onivyde)
Aliases
N/ANo risk management plan link.
